Likewise, targeting AQP5 together with targeting HER2 for BC patients with AQP5/HER2 strongly positive group may provide a potential therapeutic opportunity, considering the accumulated success of Herceptin in managing HER 2 strong positive breast cancers [36–38]. This evidence concerns the gene ERBB2 and breast carcinoma.